Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test (Lucid Diagnostics)

Lucid Diagnostics has submitted its complete clinical evidence package to Medicare’s Molecular Diagnostics Program (MolDX), seeking reconsideration of a Local Coverage Determination (LCD) to secure Medicare coverage for its EsoGuard® Esophageal DNA Test. EsoGuard is a noninvasive diagnostic tool designed to detect esophageal precancer in patients with gastroesophageal reflux disease (GERD). The submission includes six peer-reviewed studies demonstrating the test’s clinical validity, utility, and analytical accuracy.